About Merck Sharp & Dohme
Merck Sharp & Dohme is a company based in Kenilworth (United States) founded in 1890 was acquired by Onyx Equities in February 2023. Merck Sharp & Dohme has completed 2 acquisitions, including EyeBio and Merck. Merck Sharp & Dohme offers products and services including Vaccines, Medicines, and Clinical Trials. Merck Sharp & Dohme operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Kenilworth, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Merck & Co., Inc., Rahway, Nj, Usa
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$12.03 K (USD), Grant
Oct 01, 2019
-
Investors
European Union
& 2 more
-
Employee Count
Not available
-
Investments & Acquisitions
EyeBio
& 1 more
-
Acquired by
Onyx Equities
(Feb 21, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Merck Sharp & Dohme
Merck Sharp & Dohme offers a comprehensive portfolio of products and services, including Vaccines, Medicines, and Clinical Trials.
Products for preventing infectious diseases through immunization.
Treatments for conditions like oncology and immunology.
Platforms for testing new health solutions and innovations.
People of Merck Sharp & Dohme
Unlock access to complete
Unlock access to complete
Leadership Team
442 people
Software Development Team
251 people
Product Management Team
73 people
Sales and Marketing
73 people
Senior Team
64 people
Data Analysis and Operations Team
63 people
Operations Team
54 people
Finance and Accounting
30 people
Unlock access to complete
Funding Insights of Merck Sharp & Dohme
Investors in Merck Sharp & Dohme
Merck Sharp & Dohme has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include European Union, Machine Investment Group and Onyx Equities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Invests in middle market real estate opportunities, distressed debt, and special situations.
|
Locked | Locked | Locked | |
|
Acquires and manages under-performing commercial properties with full service platform.
|
Locked | Locked | Locked |
Investor details for Merck Sharp Dohme
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Merck Sharp & Dohme
Merck Sharp & Dohme has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include EyeBio and Merck.
Investment portfolio details for Merck Sharp Dohme
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for ophthalmological diseases are developed to restore vision.
|
Locked | Locked | 2021 | Locked | |
|
T-cell antibodies are developed against hematologic and solid tumor targets.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Merck Sharp Dohme
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Merck Sharp Dohme
Detailed financials for Merck Sharp Dohme
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Merck Sharp & Dohme Comparisons
Peer comparison for Merck Sharp Dohme
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Merck Sharp & Dohme
Merck Sharp & Dohme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Merck Sharp Dohme
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Merck Sharp & Dohme
Complete news archive for Merck Sharp Dohme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Merck Sharp & Dohme
Merck Sharp & Dohme was founded in 1890 and raised its 1st funding round 125 years after it was founded.
Merck Sharp & Dohme is headquartered in Kenilworth, United States.
Merck Sharp Dohme was founded in 1890 and is headquartered in Kenilworth, United States. Operations focus on pharmaceutical development within the healthcare sector. A pipeline of therapies is maintained, including MK-1439A for HIV treatment, V184 vaccine for chikungunya virus, and V937 for breast cancer. Additional portfolios address diabetes, infectious diseases, and oncology, with research extending to various therapeutic areas.
Merck Sharp & Dohme's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Merck Sharp & Dohme offers Vaccines, Medicines, and Clinical Trials.
Merck Sharp & Dohme has 3 investors. Key investors include European Union, Machine Investment Group, and Onyx Equities.